血友病インヒビター治療薬factor VIIa/factor X製剤の現状と展望-Reference-Cited by-同舟云学术

血友病インヒビター治療薬factor VIIa/factor X製剤の現状と展望

Published:2023 Issue:3 Volume:34 Page:345-354
ISSN:0915-7441
Container-title:Japanese Journal of Thrombosis and Hemostasis
language:en
Short-container-title:Nihon Kessen Shiketsu Gakkaishi

Author:

TAKAMI Eisuke¹,NAKANO Hirotoshi¹,TOMOKIYO Kazuhiko²,SHIRAHATA Akira³

Affiliation:

1. KMバイオロジクス株式会社研究開発推進部メディカルアフェアーズ課

2. 一般財団法人化学及血清療法研究所

3. 北九州八幡東病院

Publisher

Japanese Society on Thrombosis and Hemostasis

Subject

General Medicine

Link

https://www.jstage.jst.go.jp/article/jjsth/34/3/34_2023_JJTH_34_3_345-354/_pdf

Reference46 articles.

1. 1) Tomokiyo K, Nakatomi Y, Araki T, et al.: A novel therapeutic approach combining human plasma derived Factors VIIa and X for haemophiliacs with inhibitors: Evidence of a higher thrombin generation rate in vitro and more sustained haemostatic activity in vivo than obtained with Factor VIIa alone. Vox Sang 84: 290–299, 2003.

2. 2) Shirahata A, Fukutake K, Takamatsu J, et al.: A Phase II clinical trial of a mixture of plasma-derived factor VIIa and factor X (MC710) in haemophilia patients with inhibitors: Haemostatic efficacy, safety and pharmacokinetics/pharmacodynamics. Haemophilia 19: 853–860, 2013.

3. 3) van’t Veer C, Golden NJ, Mann KG: Inhibition of thrombin generation by the zymogen factor VII: Implications for the treatment of hemophilia A by factor VIIa. Blood 95: 1330–1335, 2000.

4. 4) Monroe DM, Hoffman M, Oliver JA, et al.: A possible mechanism of action of activated factor VII independent of tissue factor. Blood Coagul Fibrinolysis 9 Suppl 1: S15–20, 1998.

5. 5) Monroe DM, Hoffman M, Oliver JA, et al.: Platelet activity of high-dose factor VIIa is independent of tissue factor. Br J Haematol 99: 542–547, 1997.